Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation

International Journal of Hyperthermia

Volumn 26, Issue 5, 2010, Pages 499-513

  Gasselhuber, Astrid ^a,c   Dreher, Matthew R ^b   Negussie, Ayele ^b   Wood, Bradford J ^b   Rattay, Frank ^c   Haemmerich, Dieter ^a,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^d AMRL   (United States)

Author keywords

Drug delivery; Liposomes; LTSL; Modeling; Pharmacokinetics; Radiofrequency ablation; Tumor ablation

Indexed keywords

DOXORUBICIN; LIPOSOME; LOW TEMPERATURE SENSITIVE LIPOSOME; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TISSUE LEVEL; EXTRACELLULAR SPACE; HEAT TRANSFER; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MATHEMATICAL MODEL; PLASMA; RADIOFREQUENCY ABLATION; TISSUE PERFUSION; TUMOR ABLATION; BIOLOGICAL MODEL; COMPUTER SIMULATION; ELECTROCOAGULATION; HYPERTHERMIC THERAPY; LIVER NEOPLASMS; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; COMPUTER SIMULATION; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ELECTROCOAGULATION; HUMANS; HYPERTHERMIA, INDUCED; LIPOSOMES; LIVER NEOPLASMS; MODELS, BIOLOGICAL;

EID: 77954390311     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656731003623590     Document Type: Article

References (59)

1. Goldberg SN, Girnan GD, Lukyanov AN, Ahmed M, Monsky WL, Gazelle GS, Huertas JC, Stuart KE, Jacobs T, Torchillin VP, et al. Percutaneous tumor ablation: Increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology 2002;222:797-804.
2. Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci 2002;91:488-501.
3. Ahmed M, Lukyanov AN, Torchilin V, Tournier H, Schneider AN, Goldberg SN. Combined radiofrequency ablation and adjuvant liposomal chemotherapy: Effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol 2005;16:1365-1371.
4. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW. Magnetic resonance imaging of temperature-sensitive liposome release: Drug dose painting and antitumor effects. J Natl Cancer Inst 2007;99:53-63.
5. Goldberg SN, Saldinger PF, Gazelle GS, Huertas JC, Stuart KE, Jacobs T, Kruskal JB. Percutaneous tumor ablation: Increased necrosis with combined radio-frequency ablation and intratumoral doxorubicin injection in a rat breast tumor model. Radiology 2001;220:420-427.
6. Goldberg SN, Kamel IR, Kruskal JB, Reynolds K, Monsky WL, Stuart KE, Ahmed M, Raptopoulos V. Radiofrequency ablation of hepatic tumors: Increased tumor destruction with adjuvant liposomal doxorubicin therapy. Am J Roentgeno 2002;179:93-101.
7. Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: Principles and practice. Br J Cancer 2008;99:392-397.
8. Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005;96:10-18.
9. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988;85: 6949-6953.
10. Weinstein JN, Magin RL, Yatvin MB, Zaharko DS. Liposomes and local hyperthermia: Selective delivery of methotrexate to heated tumors. Science 1979;204:188-191.
11. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 2001;53: 285-305.
12. Mills JK, Needham D. The materials engineering of temperature-sensitive liposomes. Methods Enzymol 2004; 387:82-113.
13. El-Kareh AW, Secomb TW. A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. Neoplasia 2000;2:325-338.
14. Jackson TL. Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model. J Theor Biol 2003;220:201-213.
15. Qian F, Saidel GM, Sutton DM, Exner A, Gao J. Combined modeling and experimental approach for the development of dual-release polymer millirods. J Control Release 2002;83:427-435.
16. Qian F, Stowe N, Liu EH, Saidel GM, Gao J. Quantification of in vivo doxorubicin transport from PLGA millirods in thermoablated rat livers. J Control Release 2003;91:157-166.
17. El-Kareh AW, Secomb TW. Two-mechanism peak concentration model for cellular pharmacodynamics of Doxorubicin. Neoplasia 2005;7:705-713.
18. Ahmed M, Liu Z, Humphries S, Goldberg SN. Computer modeling of the combined effects of perfusion, electrical conductivity and thermal conductivity on tissue heating patterns in radiofrequency tumor ablation. Int J Hyperthermia 2008;24:577-588.
19. Altrogge I, Preusser T, Kroger T, Buskens C, Pereira PL, Schmidt D, Peitgen HO. Multiscale optimization of the probe placement for radiofrequency ablation. Acad Radiol 2007;14: 1310-1324.
20. Barauskas R, Gulbinas A, Vanagas T, Barauskas G. Finite element modeling of cooled-tip probe radiofrequency ablation processes in liver tissue. Comput Biol Med 2008;38:694-708.
21. Chen CC, Miga MI, Galloway Jr RL. Optimizing electrode placement using finite-element models in radiofrequency ablation treatment planning. IEEE Trans Biomed Eng 2009;56:237-245.
22. Hariharan P, Chang I, Myers MR, Banerjee RK. Radio-frequency ablation in a realistic reconstructed hepatic tissue. J Biomech EngTrans ASME 2007;129:354-364.
23. Schutt DJ, Haemmerich D. Effects of variation in perfusion rates and of perfusion models in computational models of radio frequency tumor ablation. Med Phys 2008;35: 3462-3470.
24. Pennes HH. Analysis of tissue and arterial blood temperatures in the resting human forearm. J Appl Physiol 1948;1:93-122.
25. Arkin H, Xu LX, Holmes KR. Recent developments in modeling heat transfer in blood perfused tissues. IEEE Trans Biomed Eng 1994;41:97-107.
26. Valvano JW, Cochran JR, Diller KR. Thermal conductivity and diffusivity of biomaterials measured with self-heated thermistors. Int J Thermophys 1985;6:301-311.
27. Duck F. Thermal properties of tissue. Physical Properties of Tissue. London: Academic Press; 1990. pp 167-223.
28. Haemmerich D, Chachati L, Wright AS, Mahvi DM, Lee FT Jr, Webster JG. Hepatic radiofrequency ablation with internally cooled probes: Effect of coolant temperature on lesion size. IEEE Trans Biomed Eng 2003;50: 493-500.
29. Yang D, Converse MC, Mahvi DM, Webster JG. Expanding the bioheat equation to include tissue internal water evaporation during heating. IEEE Trans Biomed Eng 2007;54:1382-1388.
30. Song CW. Effect of local hyperthermia on blood flow and microenvironment: A review. Cancer Res 1984;44: S4721-4730.
31. Brown SL, Hunt JW, Hill RP. Differential thermal sensitivity of tumour and normal tissue microvascular response during hyperthermia. Int J Hyperthermia 1992;8:501-514.
32. Van Beers BE, Leconte I, Materne R, Smith AM, Jamart J, Horsmans Y. Hepatic perfusion parameters in chronic liver disease: Dynamic CT measurements correlated with disease severity. Am J Roentgenol 2001;176:667-673.
33. Tsushima Y, Funabasama S, Aoki J, Sanada S, Endo K. Quantitative perfusion map of malignant liver tumors, created from dynamic computed tomography data. Acad Radiol 2004;11:215-223.
34. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232.
35. Brizel DM, Klitzman B, Cook JM, Edwards J, Rosner G, Dewhirst MW. A comparison of tumor and normal tissue microvascular hematocrits and red cell fluxes in a rat window chamber model. Int J Radiat Oncol Biol Phys 1993;25: 269-276.
36. Sparano JA, Speyer J, Gradishar WJ, Liebes L, Sridhara R, Mendoza S, Fry D, Egorin MJ. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. J Clin Oncol 1999;17:880-886.
37. Poon RT, Borys N. Lyso-thermosensitive liposomal doxor-ubicin: A novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother 2009;10: 333-343.
38. Doroshow JH. Anthracyclines and anthracenediones. In: LDL Chabner BA, editor. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia: Lippincott Williams &Wilkins; 2006.
39. Sylven B, Bois I. Protein content and enzymatic assays of interstitial fluid from some normal tissues and transplanted mouse tumors. Cancer Res 1960;20:831-836.
40. Yuan F, Leunig M, Berk DA, Jain RK. Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. Microvasc Res 1993;45:269-289.
41. Jain RK. Transport of molecules in the tumor interstitium: A review. Cancer Res 1987;47:3039-3051.
42. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res 1993;53:3765-3770.
43. Chen Q, Krol A, Wright A, Needham D, Dewhirst MW, Yuan F. Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome. Int J Hyperthermia 2008;24:475-482.
44. Kerr DJ, Kerr AM, Freshney RI, Kaye SB. Comparative intracellular uptake of adriamycin and 4-deoxydoxorubicin by non-small cell lung tumor cells in culture and its relationship to cell survival. Biochem Pharmacol 1986;35:2817-2823.
45. Ahmed M, Goldberg SN. Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia 2004;20:781-802.
46. Yoshida Y, Kanematsu T, Matsumata T, Takenaka K, Sugimachi K. Surgical margin and recurrence after resection of hepatocellular carcinoma in patients with cirrhosis. Further evaluation of limited hepatic resection. Ann Surg 1989;209:297-301.
47. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, Fiore F, Pignata S, Daniele B, Cremona F. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: Results in 123 patients. Ann Surg 1999;230:1-8.
48. van Duijnhoven FH, Jansen MC, Junggeburt JM, van Hillegersberg R, Rijken AM, van Coevorden F, van der Sijp JR, van Gulik TM, Slooter GD, Klaase JM, et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol 2006;13:651-658.
49. Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007;25: 978-986.
50. Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 2004;1663: 167-177.
51. Vora J, Boroujerdi M. Pharmacokinetic-toxicodynamic relationships of adriamycin in rat: Prediction of butylated hydroxyanisole-mediated reduction in anthracycline cardio-toxicity. J Pharm Pharmacol 1996;48:1264-1269.
52. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96: 133-139.
53. Workman P. Infusional anthracyclines: Is slower better? If so, why? Ann Oncol 1992;3:591-594.
54. Cusack BJ, Young SP, Driskell J, Olson RD. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxor-ubicin in the rabbit. Cancer Chemother Pharmacol 1993;32:53-58.
55. de Valeriola D. Dose optimization of anthracyclines. Anticancer Res 1994;14:2307-12013
56. Dreher MR. Improving thermal ablation using novel drug and device combinations. Paper presented at the Society for Thermal Medicine Annual Meeting, Tucson, Arizona, April 4-6, 2009.
57. Pritchard WF, Friedman MA, Karanian JW, Wray-Cahen D, Dewhirst M, Neeman Z, Hvizda J, Ashby A, Patel S, Kanter P, et al. Heat-sensitive liposomes as carriers for doxorubicin increase local drug deposition during radiofrequency ablation. Paper presented at the Radiological Society of North America Annual Meeting, Chicago, November 28-December 3, 2003.
58. Tashjian JA, Dewhirst MW, Needham D, Viglianti BL. Rationale for and measurement of liposomal drug delivery with hyperthermia using non-invasive imaging techniques. Int J Hyperthermia 2008;24:79-90.
59. Ames MM, Powis G, Kovach JS. Pharmacokinetics of anticancer agents in humans. Amsterdam: Elsevier; 1983.